I think most agree it's a tad underwhelming despite identified issues. Early stage sales momentum for a new technology in what is now a big market in dentistry (implants) you would expect to be quite large. I recently asked a young dentist whether they had heard of striate and they hadn't (it's a pretty significant practice doing implants for over a decade). In the end the next stage products should be more significant to OCC success going forward. Well funded but not expecting huge SP appreciation any time soon. GLTA
I think most agree it's a tad underwhelming despite identified...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.35 |
Change
0.105(8.47%) |
Mkt cap ! $327.2M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.37 | $1.25 | $2.832M | 2.156M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 257 | $1.35 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.36 | 5000 | 1 |
View Market Depth
| Last trade - 16.18pm 04/07/2025 (20 minute delay) ? |
| OCC (ASX) Chart |